Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

An Open-Label Phase 1b Dose-Finding Trial Evaluating the Safety of Niraparib and Temozolomide and Atezolizumab in Participants With Advanced Solid Tumors and Expansion to a Phase 2 Trial Comparing the Effects of Niraparib and Temozolomide Plus Atezolizumab vs. Atezolizumab as Maintenance Therapy in Participants With Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy (TRIO-US L-06)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03830918
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:26.707702+00:00
Published At
2026-02-12T00:00:00+00:00
Record Updated At
2026-02-12
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Advanced Malignant Solid Neoplasm", "Extensive Stage Lung Small Cell Carcinoma", "Stage III Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-02-12"
protocolSection.identificationModule.nctId
"NCT03830918"
protocolSection.identificationModule.officialTitle
"An Open-Label Phase 1b Dose-Finding Trial Evaluating the Safety of Niraparib and Temozolomide and Atezolizumab in Participants With Advanced Solid Tumors and Expansion to a Phase 2 Trial Comparing the Effects of Niraparib and Temozolomide Plus Atezolizumab vs. Atezolizumab as Maintenance Therapy in Participants With Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy (TRIO-US L-06)"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Advanced Malignant Solid Neoplasm (protocolSection.conditionsModule.conditions)
  • Extensive Stage Lung Small Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Stage III Lung Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IIIA Lung Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IIIB Lung Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IIIC Lung Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IV Lung Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IVA Lung Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IVB Lung Cancer AJCC v8 (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.